Healios K.K (TYO:4593) and Nobelpharma terminated discussions regarding a development and commercialization agreement for MultiStem in Japan, according to a Wednesday filing on the Tokyo Stock Exchange.

The decision follows unsuccessful renegotiations on the terms of the agreement after Healios opted not to proceed with a Phase 3 trial in Japan, as it was deemed unnecessary.

Price (JPY): $200.00, Change: $-1.0, Percent Change: -0.50%